Alicia Morgans, MD, MPH, is a Genitourinary Medical Oncologist and the Director of the Survivorship Program at Dana-Farber Cancer Institute.
Panelists discuss how the ARASENSE and PEACE-1 phase 3 trials demonstrated the efficacy of triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and novel antiandrogens, while addressing the ongoing underutilization of intensified treatment approaches.
Drs Morgans and Shore discuss the significance of the FDA approval of darolutamide plus ADT for metastatic castration-sensitive prostate cancer.
Panelists discuss how medical comorbidities, physiologic vs chronologic age, drug interactions, and performance status influence the choice between doublet and triplet therapy regimens.
Panelists discuss how clinical factors, including disease characteristics (Gleason score, volume, metastatic sites), patient factors (performance status, comorbidities, symptoms), and emerging genomic biomarkers, guide treatment intensification decisions in metastatic castration-sensitive prostate cancer.
Alicia Morgans, MD, MPH, discusses health-related quality of life outcomes with darolutamide plus ADT in patients with mHSPC.
Alicia Morgans, MD, MPH, details the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide for this population.
Alicia Morgans, MD, MPH, discusses the importance of managing bone and cardiac health in patients with prostate cancer receiving systemic therapy.
Alicia Morgans, MD, MPH, discusses how a lack of PSA doubling time documentation may lead to undertreatment in high-risk BCR prostate cancer.
Alicia Morgans, MD, MPH, discusses recent adjustments to Medicare Part D rules, emphasizing their positive impact on out-of-pocket costs for patients with prostate cancer.
Alicia Morgans, MD, MPH, discusses prior data and follow-up analysis of the ARAMIS trial in nonmetastatic castration-resistant prostate cancer.
Alicia Morgans, MD, MPH, discusses considerations for oncologists treating patients with nonmetastatic castration-resistant prostate cancer in the community setting.
Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.
Alicia Morgans, MD, MPH, discusses data from the ARAMIS trial showing the association between PSA levels and radiological progression in nmCRPC.
Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.
Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.
Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.
A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.
Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.
Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.
A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.
Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.
Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.
Shared insight on the role of micronized abiraterone in metastatic HSPC and how it may be utilized in practice.
Expert perspectives on metastatic hormone-sensitive prostate cancer and the current state of the treatment armamentarium.
A brief discussion on best practices in monitoring patients on therapy for nonmetastatic castration-resistant prostate cancer [nmCRPC].
A brief review of the value of quality of life measures while managing patients on therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC).
Comprehensive insight on selecting androgen receptor–targeted therapy for patients with nonmetastatic castration-resistant prostate cancer.
Focusing on nonmetastatic castration-resistant prostate cancer, panelists review the current treatment armamentarium and shared decisionmaking.
Shared insight on the respective roles of PSMA-PET imaging and PSA doubling time in the current prostate cancer treatment paradigm.
